{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    27,
    28,
    29,
    31,
    32,
    33,
    36,
    37,
    38,
    40,
    41,
    42,
    43,
    44,
    45,
    46,
    47,
    48,
    49
  ],
  "modelUsed": "gemini-3-flash-preview",
  "interventions": {
    "studyInterventions": [
      {
        "id": "int_1",
        "name": "Atezolizumab",
        "type": {
          "id": "18599f1c-9c47-4c78-85d2-a3a912381afb",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "role": {
          "id": "57d721e7-7a4b-4f54-a49f-acd1151c1b1c",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Humanized IgG1 monoclonal antibody that targets PD-L1",
        "productIds": [
          "prod_1"
        ],
        "administrationIds": [
          "admin_1"
        ]
      },
      {
        "id": "int_2",
        "name": "Bevacizumab",
        "type": {
          "id": "3b69f1c5-a72a-4797-8918-d99783f3e9d5",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "role": {
          "id": "84864ea3-cc94-4d52-a611-1b77357ff1cb",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Anti-VEGF therapy used in combination with atezolizumab",
        "productIds": [
          "prod_2"
        ],
        "administrationIds": [
          "admin_2"
        ]
      },
      {
        "id": "int_3",
        "name": "Sorafenib",
        "type": {
          "id": "662058e6-5bf7-4953-8a71-64fcd21f6d93",
          "code": "C54129",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Comparator",
          "instanceType": "Code"
        },
        "role": {
          "id": "30efc7c9-09b4-4ea7-a689-d1fa320c00f5",
          "code": "C54129",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Comparator",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Oral multi-kinase inhibitor used as the standard of care control",
        "productIds": [
          "prod_3"
        ],
        "administrationIds": [
          "admin_3"
        ]
      },
      {
        "id": "int_4",
        "name": "Entecavir",
        "type": {
          "id": "c458be78-c2d4-41a0-9eec-643db50ba438",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "31ea671b-8142-4fd8-9ff3-a51e9e909ee7",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Example of anti-HBV treatment required for patients with active HBV"
      },
      {
        "id": "int_5",
        "name": "Herbal therapies/traditional Chinese medicines",
        "type": {
          "id": "256a2a9a-6a66-4d0f-943a-f88aee10ec34",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "role": {
          "id": "dcc95511-9946-427d-bf36-8f2d6b8e05b8",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Must be discontinued prior to randomization"
      },
      {
        "id": "int_6",
        "name": "Corticosteroids",
        "type": {
          "id": "2e99e9e6-443c-4f05-8e65-d3005ce2b8e6",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "3dbd6bdd-a928-4a66-8bef-7e1df5275380",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Systemic immunosuppressive medication; prohibited within 2 weeks prior to initiation except for specific low-dose or acute cases"
      },
      {
        "id": "int_7",
        "name": "Aspirin (>325 mg/day)",
        "type": {
          "id": "7fcdad91-a5ac-408b-bbe9-6ade05e77699",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "5d3fab97-c5c8-4b66-835c-ad85e47b6852",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prohibited within 10 days of first dose"
      },
      {
        "id": "int_8",
        "name": "Strong CYP3A4 inducers",
        "type": {
          "id": "2ce9001d-5e40-4099-9bed-dfb99fea0a2c",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "e8b539f4-7f59-4c4c-b9c0-0642cd8eab63",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prohibited within 14 days prior to initiation (e.g., rifampin, St. John's wort)"
      }
    ],
    "administrableProducts": [
      {
        "id": "prod_1",
        "name": "Atezolizumab (RO5541267)",
        "administrableDoseForm": {
          "id": "9e6dba0c-fd34-47e2-a851-c382cb3245d7",
          "code": "C42945",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Injection",
          "standardCode": {
            "id": "362d9e25-9efd-49f2-81ee-2eb059a65d9d",
            "code": "C42945",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Injection",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "50f2b51c-41b2-471f-88f4-4ece595b5119",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "Not specified",
        "substanceIds": [
          "sub_1"
        ],
        "manufacturer": "F. Hoffmann-La Roche Ltd"
      },
      {
        "id": "prod_2",
        "name": "Bevacizumab (RO4876646)",
        "administrableDoseForm": {
          "id": "527047e8-e22c-44a7-b788-e1f8a6240006",
          "code": "C42945",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Injection",
          "standardCode": {
            "id": "52ab7a0f-5d4c-4245-b84c-3d1c4af47bed",
            "code": "C42945",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Injection",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "452d8fcf-cce0-467f-bf6d-bd2966ca9986",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "Not specified",
        "substanceIds": [
          "sub_2"
        ],
        "manufacturer": "F. Hoffmann-La Roche Ltd"
      },
      {
        "id": "prod_3",
        "name": "Sorafenib",
        "administrableDoseForm": {
          "id": "403e3dc9-7c62-46b1-94af-fb6dcfdad22f",
          "code": "C42998",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Tablet",
          "standardCode": {
            "id": "45debed0-8456-4d24-acec-c1558da23876",
            "code": "C42998",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Tablet",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "b6afc0dc-3b38-4d60-a4bf-eae8b0eaf66b",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "Not specified",
        "substanceIds": [
          "sub_3"
        ],
        "manufacturer": "Not specified"
      }
    ],
    "administrations": [
      {
        "id": "admin_1",
        "name": "Arm A: Atezolizumab",
        "instanceType": "Administration",
        "dose": "1200 mg",
        "doseFrequency": "Every 3 weeks (Q3W)",
        "route": {
          "code": "Intravenous",
          "codeSystem": "USDM",
          "decode": "Intravenous"
        },
        "duration": "Until unacceptable toxicity or loss of clinical benefit"
      },
      {
        "id": "admin_2",
        "name": "Arm A: Bevacizumab",
        "instanceType": "Administration",
        "dose": "15 mg/kg",
        "doseFrequency": "Every 3 weeks (Q3W)",
        "route": {
          "code": "Intravenous",
          "codeSystem": "USDM",
          "decode": "Intravenous"
        },
        "duration": "Until unacceptable toxicity or loss of clinical benefit"
      },
      {
        "id": "admin_3",
        "name": "Arm B: Sorafenib",
        "instanceType": "Administration",
        "dose": "400 mg",
        "doseFrequency": "Twice a day (BID)",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "Continuously until unacceptable toxicity or loss of clinical benefit"
      }
    ],
    "substances": [
      {
        "id": "sub_1",
        "name": "Atezolizumab",
        "instanceType": "Substance",
        "description": "Anti-PD-L1 monoclonal antibody"
      },
      {
        "id": "sub_2",
        "name": "Bevacizumab",
        "instanceType": "Substance",
        "description": "Anti-VEGF monoclonal antibody"
      },
      {
        "id": "sub_3",
        "name": "Sorafenib",
        "instanceType": "Substance",
        "description": "Multi-kinase inhibitor"
      }
    ],
    "medicalDevices": [],
    "summary": {
      "interventionCount": 8,
      "productCount": 3,
      "deviceCount": 0
    }
  },
  "rawResponse": {
    "interventions": [
      {
        "name": "Atezolizumab",
        "role": "Investigational Product",
        "description": "Humanized IgG1 monoclonal antibody that targets PD-L1"
      },
      {
        "name": "Bevacizumab",
        "role": "Investigational Product",
        "description": "Anti-VEGF therapy used in combination with atezolizumab"
      },
      {
        "name": "Sorafenib",
        "role": "Comparator",
        "description": "Oral multi-kinase inhibitor used as the standard of care control"
      },
      {
        "name": "Entecavir",
        "role": "Concomitant Medication",
        "description": "Example of anti-HBV treatment required for patients with active HBV"
      },
      {
        "name": "Herbal therapies/traditional Chinese medicines",
        "role": "Prior Medication",
        "description": "Must be discontinued prior to randomization"
      },
      {
        "name": "Corticosteroids",
        "role": "Concomitant Medication",
        "description": "Systemic immunosuppressive medication; prohibited within 2 weeks prior to initiation except for specific low-dose or acute cases"
      },
      {
        "name": "Aspirin (>325 mg/day)",
        "role": "Concomitant Medication",
        "description": "Prohibited within 10 days of first dose"
      },
      {
        "name": "Strong CYP3A4 inducers",
        "role": "Concomitant Medication",
        "description": "Prohibited within 14 days prior to initiation (e.g., rifampin, St. John's wort)"
      }
    ],
    "products": [
      {
        "name": "Atezolizumab (RO5541267)",
        "doseForm": "Injection",
        "strength": "Not specified",
        "manufacturer": "F. Hoffmann-La Roche Ltd"
      },
      {
        "name": "Bevacizumab (RO4876646)",
        "doseForm": "Injection",
        "strength": "Not specified",
        "manufacturer": "F. Hoffmann-La Roche Ltd"
      },
      {
        "name": "Sorafenib",
        "doseForm": "Tablet",
        "strength": "Not specified",
        "manufacturer": "Not specified"
      }
    ],
    "substances": [
      {
        "name": "Atezolizumab",
        "description": "Anti-PD-L1 monoclonal antibody"
      },
      {
        "name": "Bevacizumab",
        "description": "Anti-VEGF monoclonal antibody"
      },
      {
        "name": "Sorafenib",
        "description": "Multi-kinase inhibitor"
      }
    ],
    "administrations": [
      {
        "name": "Arm A: Atezolizumab",
        "dose": "1200 mg",
        "frequency": "Every 3 weeks (Q3W)",
        "route": "Intravenous",
        "duration": "Until unacceptable toxicity or loss of clinical benefit"
      },
      {
        "name": "Arm A: Bevacizumab",
        "dose": "15 mg/kg",
        "frequency": "Every 3 weeks (Q3W)",
        "route": "Intravenous",
        "duration": "Until unacceptable toxicity or loss of clinical benefit"
      },
      {
        "name": "Arm B: Sorafenib",
        "dose": "400 mg",
        "frequency": "Twice a day (BID)",
        "route": "Oral",
        "duration": "Continuously until unacceptable toxicity or loss of clinical benefit"
      }
    ],
    "devices": []
  }
}